NCT05502692View on ClinicalTrials.gov

CHARACTERISE - A Cross-sectional, Observational Study to Characterise the Transition to Dolutegravir-based Regimens in South Africa in Terms of the Emergence of Obesity, Viral Re-suppression and Integration Into Routine Programme Care

CompletedOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

July 12, 2022

Primary Completion Date

December 30, 2022

Study Completion Date

March 30, 2023

Conditions
Dolutegravir
Interventions
BEHAVIORAL

CHARACTERISE

Cohort 1 Cohort 2

Trial Locations (1)

2193

Sunnyside Office Park, Johannesburg

All Listed Sponsors
collaborator

UNITAID

OTHER

lead

University of Witwatersrand, South Africa

OTHER